Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.38 |
| ▸ | HTR2A | P28223 | 3/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.35 |
| ▸ | HTR2B | P41595 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17193929 | 0.85 | HTR2C (0.45) | HTR2CHTR2ACA1CA2PDE3A | |
| SCHEMBL19830046 | 0.79 | KDM1A (0.35) | HTR2CHTR2ACA1CA2PDE3A | |
| SCHEMBL19827864 | 0.79 | KDM1A (0.35) | HTR2CHTR2ACA1CA2PDE3A | |
| SCHEMBL19830045 | 0.79 | KDM1A (0.35) | HTR2CHTR2ACA1CA2PDE3A | |
| SCHEMBL19827857 | 0.79 | KDM1A (0.35) | HTR2CHTR2ACA1CA2PDE3A | |
| SCHEMBL15896884 | 0.78 | SLC6A2 (0.37) | HTR2CHTR2ASLC6A4SLC6A2SLC6A3 | |
| SCHEMBL13616555 | 0.78 | SLC6A2 (0.37) | HTR2CHTR2ASLC6A4SLC6A2SLC6A3 | |
| SCHEMBL30743773 | 0.78 | SLC6A2 (0.37) | HTR2CHTR2ASLC6A4SLC6A2SLC6A3 | |
| SCHEMBL18469565 | 0.78 | HTR2C (0.36) | HTR2CHTR2ACA1CA2PDE3A | |
| SCHEMBL10696858 | 0.77 | HTR2C (0.44) | HTR2CHTR2ASLC6A4SLC6A2CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3133071-A1 | C-ARYL INDICAN DERIVATIVE, AND PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR AND USES THEREOF | Shanghai De Novo Pharmatech Co Ltd. (CN) | 2017-02-22 | — | — | EP | disclosed |
| US-20170037038-A1 | C- ARYL GLYCOSID DERIVATIVES, PHARMACEUTICAL COMPOSITION, PREPARATION PROCESS AND USES THEREOF | SHANGHAI DE NOVO PHARMATECH CO. LTD. (CN) | 2017-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037038-A1 | C- ARYL GLYCOSID DERIVATIVES, PHARMACEUTICAL COMPOSITION, PREPARATION PROCESS AND USES THEREOF | SLC5A2, SLC5A1, MGAT1 | HTR2C 1269/4885HTR2A 1802/4885CA1 1948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.